MedTrace Logo

Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula

NCT02431377 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-11-03

No results posted yet for this study

Summary

A single center, non-controlled trial to document the gastrointestinal (GI) tolerability of the study formula (SF), containing a whey protein concentrate enriched with alpha-lactalbumin (WPC alpha-lac) fed for 6 weeks to healthy, term infants.

Conditions

  • Infant Formula Intolerance

Interventions

OTHER

S-26 Gold

A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Elvira M Estorninos, MD · Asian Hospital and Medical Center

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Days
Max Age
35 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-09-30
Completion
2015-10-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431377 on ClinicalTrials.gov